OSCR
Oscar Health, Inc.
OSCR has the edge over RPRX overall, supported by stronger modeled upside and stronger valuation.
RPRX
Royalty Pharma plc
RPRX trails on the overall score without a compensating advantage in the available component scores.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RPRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Weak |
RPRX's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over RPRX in the historical PE scenario, which offers more potential upside but is not a forecast.
RPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $68.97 | — |
| Cheap | 15x | $22.76 | -67% |
| Fair | 23x | $34.85 | -49% |
| Expensive | 44x | $66.74 | -3.2% |
| Current | 45x | $68.97 | — |
Historical ranges are pointers, not guarantees.
RPRX's PE is in its expensive range at 45x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RPRX on the outlook, with more favorable revenue expectations.
RPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| -- | |
| Limited | |
| High |
Analysts expect RPRX's earnings to grow, with its revenue and profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RPRX on earnings, with more consistent year-over-year improvement.
RPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.95 | +292% |
| Q3 2026 | $1.52 | -13% |
| Q2 2026 | $1.87 | -18% |
| Q1 2026 | $1.90 | -22% |
| Q4 2025 | $1.78 | -6.8% |
| Q3 2025 | $1.75 | -32% |
| Q2 2025 | $2.29 | +52% |
| Q1 2025 | $2.45 | +38% |
| Q4 2024 | $1.91 | -25% |
RPRX's earnings per share have fallen from their peak: $1.52 over the past year, against $3.36 in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RPRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $690.1M | +13% |
| Q2 2026 | $674.1M | +16% |
| Q1 2026 | $630.6M | +11% |
| Q4 2025 | $622M | +4.8% |
| Q3 2025 | $609.3M | +7.9% |
| Q2 2025 | $578.7M | +7.7% |
| Q1 2025 | $568.2M | 0% |
| Q4 2024 | $593.6M | -0.4% |
RPRX's revenue has grown year over year for seven quarters in a row: $690M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 60% | -11 points |
| Q2 2026 | 20% | -17 points |
| Q1 2026 | 89% | -4.7 points |
| Q4 2025 | 62% | +1.5 points |
| Q3 2025 | 70% | -60 points |
| Q2 2025 | 36% | -14 points |
| Q1 2025 | 94% | +107 points |
| Q4 2024 | 61% | -42 points |
RPRX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RPRX on cash flow, with more consistent year-over-year improvement.
RPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $686.1M | -2.4% |
| Q2 2026 | $728.5M | +100% |
| Q1 2026 | $718.2M | +20% |
| Q4 2025 | $827.1M | +11% |
| Q3 2025 | $702.6M | -0.1% |
| Q2 2025 | $364M | -45% |
| Q1 2025 | $596.1M | -10% |
| Q4 2024 | $742.5M | -3.9% |
RPRX's free cash flow has been positive every quarter for six years: $3B over the past year, up 23% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +105K shares |
| 1 year | -0.5% | -2.6M shares |
| 3 years | -7.3% | -44.1M shares |
| 5 years | -8.3% | -50.1M shares |
| Available history | +58% | +205M shares |
RPRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $86.3M |
| Q2 2026 | $44.6M |
| Q1 2026 | $50.1M |
| Q4 2025 | $80.5M |
| Q3 2025 | $146.5M |
| Q2 2025 | $291.6M |
| Q1 2025 | $708.8M |
| Q4 2024 | $52.6M |
RPRX spent $262M buying back its own shares over the past year, down 78% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over RPRX on leverage, with a lower net debt burden relative to earnings.
RPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.4x | High |
| Q2 2026 | 5.4x | High |
| Q1 2020 | 2.2x | Moderate |
| Q4 2019 | 2.2x | Moderate |
RPRX's net debt is about 5.4 years of its operating earnings (EBITDA).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.0 | Overbought |
| Stochastic | 89.9 | Overbought |
RPRX's weekly RSI is 74 (overbought) and its Stochastic is 90 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over RPRX on valuation relative to its sector.
RPRX PE vs Healthcare Sector
| Metric | RPRX | Sector median | Relative |
|---|---|---|---|
| PE | 45x | 26x | 76% above |
| PE % | 84 | 31 | 53 pts above |
RPRX is trading at 45x earnings, a 76% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
RPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.6 | 10% above |
| 20 week MA | $60.4 | 14% above |
| 50 week MA | $52.2 | 32% above |
| 100 week MA | $43.1 | 60% above |
| 200 week MA | $36.5 | 89% above |
RPRX is in an uptrend: it's above all five of its weekly moving averages, and 89% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RPRX on returns for 2026, with the stronger performance.
RPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.0 | $48.9 | -0.2% |
| 2021 | $48.9 | $40.3 | -18% |
| 2022 | $40.3 | $39.4 | -2% |
| 2023 | $39.4 | $28.1 | -29% |
| 2024 | $28.1 | $25.5 | -9.1% |
| 2025 | $25.5 | $39.2 | +54% |
| 2026 YTD | $39.2 | $69.0 | +76% |
RPRX is up 76% so far in 2026, after finishing lower in five of the previous six years.